Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Debt to Equity (2019 - 2023)

Immunovant filings provide 4 years of Debt to Equity readings, the most recent being $0.0 for Q1 2023.

  • Quarterly Debt to Equity rose 165.28% to $0.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $0.0 through Mar 2023, up 165.28% year-over-year, with the annual reading at $0.0 for FY2023, 165.28% up from the prior year.
  • Debt to Equity hit $0.0 in Q1 2023 for Immunovant, up from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.03 in Q1 2020 and bottomed at -$0.41 in Q2 2019.
  • Average Debt to Equity over 4 years is -$0.05, with a median of $0.0 recorded in 2023.
  • Peak annual rise in Debt to Equity hit 329.09% in 2020, while the deepest fall reached 100.28% in 2020.
  • Immunovant's Debt to Equity stood at $0.03 in 2019, then crashed by 98.91% to $0.0 in 2020, then rose by 19.08% to $0.0 in 2022, then skyrocketed by 165.28% to $0.0 in 2023.
  • Per Business Quant, the three most recent readings for IMVT's Debt to Equity are $0.0 (Q1 2023), $0.0 (Q1 2022), and $0.0 (Q3 2020).